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ABSTRACT  
Pulmonarins A and B are two new dibrominated marine acetylcholinesterase inhibitors which 
were isolated and characterised from the sub-Arctic ascidian Synoicum pulmonaria collected off 
the Norwegian coast. The structures of natural pulmonarins A and B were tentatively elucidated 
by spectroscopic methods and later verified by comparison with synthetically prepared material.  
Both pulmonarins A and B displayed reversible, non-competitive acetylcholinesterase inhibition 
comparable to several known natural acetylcholinesterase inhibitiors. Pulmonarin B was the 
strongest inhibitor with an inhibition constant (Ki) of 20 µM. In addition to reversible, non-
competitive acetylcholinesterase inhibition, the compounds displayed weak antibacterial activity 
but no cytotoxicity or other investigated bioactivities. 
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Marine invertebrates and their associated bacterial symbionts represent organisms with great 
potential for the discovery of novel bioactive compounds and chemical scaffolds.1-3 The sessile 
benthic lifestyle promotes the production of defensive secondary metabolites to provide an 
evolutionary advantage. To investigate their potential as sources for bioactive compounds, 
several hundred different Arctic marine invertebrates, algae and microorganisms have been 
collected during a systematic study of Arctic marine organisms along the Norwegian coast.4 The 
Arctic waters provide a significantly less studied biotope in comparison to warmer waters, 
however they are still rich in biodiversity.4-6 One such Arctic organism, the colonial ascidian 
Synoicum pulmonaria has been shown to contain a family of dibrominated bioactive compounds 
known as the synoxazolidinones.7-9 In the current paper, further studies of the extract from S.  







The pulmonarins are structurally related to the synoxazolidinones (3-5) which are heavily 
modified antimicrobial dipeptide derivatives displaying a rare 4-oxazolidinone core linking a 
dibrominated tyrosine derivative to an arginine/agmatine side chain. The pulmonarins do not 
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display the 4-oxazolidinone core or the guanidine group of the synoxazolidinones but instead 
they contain quaternary ammonium groups implying potential acetylcholinesterase (AChE) 
inhibiting properties. AChE inhibitors are a class of drugs used for the treatment of Alzheimer’s 
disease, glaucoma, myasthenia gravis (an autoimmune disorder) and the recovery of 
neuromuscular block after surgery.10, 11 Some well-known AChE-inhibitors in clinical use today 
include physostigmine (6), a naturally occurring carbamate from the Calabar bean, used for the 
treatment of glaucoma.10, 12 Examples of other current AChE-inhibitor based drugs are 
galanthamine (7) and donepezil, both used in most countries for the treatment of Alzheimer’s 
disease. Several toxins such as nerve agents, insecticides and antiparasitic chemicals used in 
agriculture and aquaculture also act by inhibiting AChE and consist mostly of organophosphorus 
compounds and carbamates.13, 14 At least three other marine natural products with similar 
structures to 1 and 2 have been reported in the literature. Compound 8, with significant structural 
similarities to 1 was isolated by Fattorusso et al. from the Caribbean sponge Pseudoceratina 
crassa (later reclassified as Aiolochroia crassa) in 1994.15  Compound 8 was recently studied by 
Munoz and co-workers and shown to display weak antiparasitic properties.16 Compound 9 was 
isolated from another Caribbean sponge Verongula sp. but no biological activity was reported for 






















The current paper describes the isolation, structural characterisation and syntheses of 1 and 2 and 
the evaluation of their biological acitivities including AChE inhibition employing electric eel 
AChE.  
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RESULTS AND DISCUSSION 
Step-wise fractionation of an aqueous extract of S. pulmonaria resulted in the isolation of two 
compounds. The aqueous extract was loaded on a solid phase extraction (SPE) cartridge and 
eluted with 40/60 CH3CN/H2O. The eluate was loaded on a semi-preparative RP-HPLC C18-
column. MS analysis revealed compounds with isotope patterns indicating dibrominated 
compounds. Compounds 1 and 2 were isolated as yellow gels with the molecular formula 
C13H18Br2O3N for 1 and C17H27Br2O2N2 for 2. Database searching suggested new compounds 
and their tentative structures were solved on the basis of a number of 1D and 2D NMR 
experiments and mass spectometric analyses. Spectroscopic similarities with the 
synoxazolidinones were rapidly established.7 Table 1 lists proton and carbon NMR shift values 

















Table 1. 1D and 2D NMR Data (600/175 MHz DMSO-d6) of Natural 1 and 2. 
  no δC , typea δH (mult, J in Hz)   gCOSY gHMBC 
Pulmonarin A     
1 61.2, CH3 3.84, s  2 
2 158.2, C    
3/3’ 118.5, C    
4/4’ 133.9, CH 8.15, s  2, 3/3’, 4/4’, 6 
5 *    
6 163.2, C    
7 59.9, CH2 4.66, m 8  
8 64.2, CH2 3.78, t (4.5) 7 9 
9/9’/9’’ 53.3, CH3 3.14, s  8 
     
Pulmonarin B     
1 60.9, CH3 3.77, s  2 
2 151.9, C    
3/3’ 117.0, C    
4/4’ 133.7, CH 7.53, s  2, 3/3’, 4/4’ 
5 136.1, C    
6 41.0, CH2 3.38, s  4/4’, 5, 7 
7 169.3, C    
8 NH 8.19, t (5.5) 9  
9 38.9, CH2 3.05, m 8, 10  
10 29.0, CH2 1.45, m 9, 11  
11 23.8, CH2 1.25, m 10, 12  
12 22.3, CH2 1.66, m 11, 13  
13 65.2, CH2 3.24, m 12  
14/14’/14’’ 52.2, CH3 3.02, s  13, 14 
           a Carbon shifts obtained from gHSQC and gHMBC experiments. * Not observed 
 
An initial inspection of the 2D NMR data revealed similar motifs in the aromatic region as those 
found in the synoxazolidinones.7 The carbon shifts (Table 1) used for the structure elucidation 
were obtained from the gHSQC experiment, while the quaternary carbon signals are derived 
from gHMBC data by comparison with the structurally related synoxazolidinones isolated from 
the same organism. The tentative structure of 1 was solved based on the following correlations: 
The gHMBC correlation from the H-1 methoxy protons to C-2 indicated the position of the 
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methoxy group on the substituted aromatic ring; the shift value of C-3/3’ (δC 118.5) was 
indicative of two bromine atoms at these positions7; and protons H-4/4’showed a gHMBC 
correlation to the ester carbonyl C-6. Furthermore, a gCOSY correlation was observed between 
the two adjacent methylene protons H-7 and H-8 and the high chemical shift of H-7 (δH 4.66) 
placed it adjacent to the ester oxygen. The gHMBC correlation from protons H-9/9’/9’’ to C-8 
supported the terminal trimethylated quaternary ammonium. The shift values of C-9/9’/9’’ (δC 
53.3) and H-9/9’/9’’ (δH 3.14) are consistent with literature values.19-21 The assignment of the 
terminal trimethylated ammonium was also supported by a loss of 59 mass units from the parent 
ion as indicated by a prominent peak at m/z 334 in the mass spectrum of 1.  
 
Compound 2 displayed signals in the aromatic area of the 1H and 13C NMR spectra that were 
nearly identical to 1, suggesting a similar sub-structure. The chemical shift of H-4/4’ is 
somewhat lower than that of the corresponding protons found in both 1 and the 
synoxazolidinones due to the methylene at C-6. The H-6 methylene protons displayed a high 
shift (δH 3.38) and showed gHMBC correlations to C-4/4’, C-5 and the amide carbonyl C-7 
placing it between the amide and the aromatic ring. The chemical shifts for H-6, C-6 and C-7 
correlated well with a similar synthetic methoxy phenyl acetamide derivative of orthidine F.22  
C-9 was placed next to the amide nitrogen based on gCOSY correlations between amide proton 
H-8 and H-9. This spin system further involved H-10 to H-13 generating a saturated five carbon 
segment between the amide and terminal trimethyl ammonium which was further verified by the 
gHMBC correlations from protons H-14/14’/14’’ to C-13 in analogy to 1. This spin system 
matched well with the chemical shifts of the analogous spin system reported for clavatadine D, 
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isolated from the Australian sponge Suberea clavata.23 Figure 1 shows key gHMBC and gCOSY 



















Figure 1. Key gHMBC (H→C) and gCOSY (▬) correlations of 2. 
 
 
Because the purification led to sample loss, and the incomplete NMR data of the compounds, 
total synthesis was required to generate sufficient material for structural verification and 
biological testing. Compound 1 was prepared in one step. DCC was used as coupling agent to 
react 3,5-dibromo-4-methoxybenzoic acid and choline chloride in the presence of a catalytic 
amount of DMAP in CH2Cl2. The reaction was slow and sufficient amounts of 1 could only be 
obtained after an extended reaction time followed by HPLC purification. Several different 
solvent systems were evaluated, but only CH2Cl2 generated 1 due to solubility issues. Compound 
2 was synthesised in three steps from 4-methoxyphenylacetic acid which was initially 
dibrominated with Br2/FeBr3 to produce 3,5-(dibromo-4-methoxyphenyl)acetic acid (2a) 
according to Weller et al.24 The bromination reaction was followed with MS and a complete 
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conversion to the desired dibrominated product required additional  Br2/FeBr3 after 24 h. 
Compound 2a was then coupled with 5-(dimethylamino)amylamine using HBTU as coupling 
agent to generate 2-(3,5-dibromo-4-methoxyphenyl)-N-(5-(dimethylamino)pentyl)acetamide 
(2b). N-methylation of 2b with CH3I completed the synthesis of 2. The synthetic routes to 1 and 












Scheme 1. Synthesis of 1 and 2. Reagents, conditions, isolated yield (a) Choline chloride, 
DMAP, DCC, CH2Cl2, rt, 6 days, 4% (HPLC yield); (b) Br2/FeBr324, CHCl3, rt, 48h, 21%; (c) 
HBTU, DIPEA, DMF, rt, 16h, not isolated; (d) K2CO3, CH2Cl2; 16 h, 13% (HPLC yield). 
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Both 1H and 13C NMR shifts of the natural and synthetic compounds are analogous, thus 
validating their proposed structures (Table S3). This is further supported by comparing the 2D-
NMR data. 
 
The para-methoxy dibrominated phenyl group moiety is a common structural motif among 
marine secondary metabolites, and particularly those that are tyrosine derivatives.25 The isolated 
compounds bear structural resemblances with not only the synoxazolidinones,7, 8 and 8, 9 and 
1015, 17, 18 but also with  ianthelline,26 and subereamine B27  amongst others. 
 
As both pulmonarins are terminally trimethylated ammonium compounds they were evaluated as 
AChE inhibitors in addition to the standard screens routinely performed during our screening 
process.4 Electric eel AChE, sharing a high degree of sequence homology and having a 3D 
structure very similar to human AchE,28  was employed as a model vertebrate AChE system and 
the well-established method of Ellman was employed to study the inhibition kinetics.29, 30 
Synthetic 1 induced 50% inhibition of electric eel AChE at 42 µg/mL (105 µM) in the presence 
of acetylthiocholine chloride as a substrate (Figure 2). The inhibitory constant (Ki) was 
determined from the Dixon plot31 and revealed 1 to be a reversible, non-competitive inhibitor 
with a Ki of 36 µg/mL (90 µM) (Figure 3). Compound 2 showed a stronger reversible, non-
competitive inhibition and 50% inhibition was obtained at 16 µg/mL (35 µM) with a Ki of 9 










Figure 2. Inhibition of vertebrate AChE by 1 and 2. 50% inhibition was observed at 42 and 16 








Figure 3. Determination of the type of inhibition and the inhibition constant Ki  for 1 (left graph) 
and 2 (right graph) by Dixon plot analysis. The concentrations of the substrate acetylthiocholine 
were 0.25 (), 0.5 (), and 1 mM (). Ki was determined to 36 g/mL (90 µM)  for 1 and to 9 
g/mL (20 µM)  for 2. 
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A Ki of 9 g/mL (20 µM) for 2 indicates moderate binding affinities for  vertebrate AChE, 
similar to that of the FDA-approved drug galanthamine.32 The affinity of 1 for AChE is four 
times weaker. AChE inhibitors with significantly varying binding affinities are used in approved 
medications. Physostigmine is a strong AChE inhibitor with an IC50 value of approximately 30 
nM33 while galanthamine, used to combat Alzheimer’s disease, displays a moderate Ki of 2-20 
µM against AChE from different vertebrate species.32 The Ki values obtained here are therefore 
within the pharmaceutically interesting regime. For competitive inhibitors of AChE, studies 
based on molecular modelling and quantitative structure-activity relationship (QSAR) analysis 
have shown that a degree of hydrophobicity and the presence of an ionisable nitrogen are pre-
requisites for the inhibitor-enzyme interactions.10 Considering this, it was expected that the more 
hydrophobic 1, as determined by HPLC retention times, would be more active. As the observed 
AChE inhibition contradicts this, it is clear that further investigations are required for a 
mechanistic explanation. 
 
As an allosteric inhibitor of AChE, the presence of a quaternary nitrogen in both compounds 
suggests binding through electrostatic interactions at the peripheral anionic site (PAS) of the 
enzyme, which is located on the surface of the protein at the entrance of the active site cleft. This 
site is implicated in a number of non-classical functions such as amyloid deposition, cell 
adhesion and neurite outgrowth.34 The PAS is thus a potential target in rational drug design for 
the development of novel and improved inhibitors and therapeutics for the treatment of neural 
cancers, nerve regeneration and neurodegenerative disorders such as Alzheimer's disease.11, 34 
QSAR studies of 1 and 2 could potentially contribute to future development of new drug 
candidates in various therapeutic fields. 
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We have previously reported that the 40/60 (v/v) CH3CN/H2O SPE fraction of S. pulmonaria 
exhibited antibacterial activity against a number of bacteria, showing an activity of 160 µg/ml 
against Corynebacterium glutamicum and 80 µg/ml against Staphylococcus aureus.35 These 
compounds were therefore also included in the extensive screening performed at MabCent to 
investigate other potential bioactivities.4 A lack of activity at concentrations above 100 µg/mL 
classified the compounds as “inactive” in all assays apart from the antibacterial screen. 
Compound 1 displayed only very mild activity against one bacterial strain, C. glutamicum, at a 
concentration of 500 µg/mL indicating a possible synergistic effect in the active fraction. 
Compound 2 was slightly more active against C. glutamicum displaying a minimal inhibitory 
concentration of 250 µg/mL. No activities were seen in the other bacterial screens in our panel 
(test strains used were S. aureus (ATTC 9144), E. coli (ATCC 25922), P. aeruginosa (ATTC 
27853), and C. glutamicum (ATTC 13032)) (data not included). As well as testing negative 
against other bacteria, both 1 and 2 also tested negative for cytotoxic activities against three 
adherent cancer cell lines (A2058 melanoma, HT29 colon carcinoma and MCF7 breast 
carcinoma cells) and against adherent, non-malignant lung fibroblasts (MRC-5 cells)  (data not 
included). They were also inactive in an anti-inflammatory assay targeted against TNF-α and in a 
biofilm formation inhibition assay using S. epidermidis (ATCC 35984) (data not included). 
Finally 1 and 2 were shown to be inactive as cellular antioxidants (data not included). 
Compounds 1 and 2 thus appear to possess a highly specific action as reversible non-competitive 
AChE inhibitors displaying no apparent cellular toxicity. As reported for the synoxazolidinones 
(3-5), it was not possible to determine whether symbiotic microorganisms are responsible for the 
biosynthesis of 1 and 2 which is a common case for marine natural products.1 Based on the key 
structural differences between the synoxazolidinones and the compounds in the present study it 
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seems unlikely that they share a common biosynthetic route in the organism apart from being 
tyrosine derivatives. Compound 1 can be considered as a dibrominated version of p-
hydroxybenzoylcholine which has been isolated from the seeds of Sinapis albae and it was 
proposed to originate biosynthetically from a p-hydroxy benzyl alcohol derivative.36, 37 An 
analogous biosynthetic route towards 1 is therefore plausible. The proposed biosynthesis of 2 is 
similar and is suggested to be derived from amide formation between methylated 2-(4-hydroxy-





Two new marine bioactive compounds have been isolated and characterised from S. pulmonaria. 
Curtailed by the lack of the natural compounds, total synthesis provided enough material for 
structure verification and biological testing. Both compounds turned out to be nontoxic, 
reversible, non-competitive inhibitors of AChE. The isolation of 1 and 2 yet again demonstrates 
the chemical diversity of the cold-water marine organism S. pulmonaria and the potential of the 
species for the discovery of new structural motifs for further lead compound development in a 




General Experimental Procedures 
UV spectrum was determined on a Lambda 25 spectrometer from Perkin Elmer Instruments. 
Infrared spectra were recorded on an Avatar 320 FT-IR spectrometer from Nicolet. 1D and 2D 
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NMR spectra of natural products were recorded on a Varian VNMRS 600 MHz spectrometer in 
DMSO-d6. Carbon resonances were derived from gHSQC and gHMBC experiments. NMR 
spectra of synthetic compounds were recorded on a Varian 7000e 400 MHz spectrometer in 
DMSO-d6. Chemical shifts were referenced to the residual solvent peaks, δH 2.50 and δC 39.5. 
Mass spectra were acquired on a LTQ Orbitrap XL Hybrid Fourier Transform mass spectrometer 
from Thermo Scientific and the Thermo Scientific Accela HPLC-LTQ Ion Trap-Orbitrap 
Discovery system. HPLC of synthetic compounds was performed on a 1200 series instrument 
with a binary pump and a photodiode array detector from Agilent Technologies. All starting 
materials were purchased from Sigma-Aldrich apart from 5-(dimethylamino)amylamine which 
was provided by Matrix Scientific. Chemicals were used without further purification except for 
methyl iodide which was distilled and stored over Cu (s) prior to use. Electric eel AChE (6.25 
U/mL) was provided by Sigma-Aldrich. 
 
Extraction and Purification of Pulmonarins A and B  
Specimens of Synoicum pulmonaria (Ellis and Solander, 1786) were collected off the coast of 
Tromsø in northern Norway and identified by Professor Bjørn Gulliksen (Department of Arctic 
and Marine Biology, University of Tromsø, Tromsø, Norway). The organisms are stored at the 
Norwegian College of Fishery Science, University of Tromsø, Norway. Specimens (80 g, wet 
weight) of the organism were pooled, lyophilised and extracted with 10 volumes (v/w) of 60/40 
CH3CN/H2O containing 0.1% TFA, at 4 °C. The supernatant was removed after 24 h and the 
extraction procedure was repeated. The combined supernatants were then placed in a -20 °C 
freezer for 2 h, resulting in phase separation between a CH3CN rich organic phase and an 
aqueous phase. The aqueous phase was loaded on a C18 solid phase extraction (SPE) cartridge 
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and eluted with 10, 40 and 80% CH3CN. The 40% CH3CN SPE eluate was subsequently loaded 
on a semi-prep HPLC (column; Waters, Sunfire C18, 250 × 10 mm) with photodiode array 
(PDA) detection. Compounds 1 (3.0 mg) and 2 (3.9 mg) were eluted  after 41.9 min and 38.4, 
min respectively, using a gradient of 0% to 40% CH3CN/0.05% TFA in H2O.  
  
Pulmonarin A (1). Yellow gel; UV (MeOH) λmax (log ε) 221 nm (4.4); IR vmax 3036, 1684, 
1474, 1200, 1123 cm-1; 1H and 13C NMR data, see Table 1.  HRESIMS m/z 393.9650 [M]+  
(calcd for C13H1879Br2O3N, 393.9654).  
 
Pulmonarin B (2). Yellow gel. UV (MeOH) λmax (log ε) 220 nm (4.5); IR vmax 3036, 1688, 
1473, 1200, 1125 cm-1; 1H and 13C NMR data, see Table 1.  HREIMS m/z  449.0439 for [M]+ 




2-((3,5-dibromo-4-methoxybenzoyl)oxy)-N,N,N-trimethylethanaminium chloride (1) 
DCC (1.12 g, 3 equiv., 5.40 mmol), 1.68 g of 3,5-dibromo-4-methoxybenzoic acid (1.5 equiv., 
5.40 mmol) and 0.16 g of DMAP (0.2 equiv., 1.28 mmol) were added to 2-hydroxy-N,N,N-
trimethylethanaminium chloride (0.67 g, 4.80 mmol) in 10 mL of CH2Cl2. The mixture was 
stirred at room temperature (rt) for 6 days. A white solid was obtained which was extracted with 
H2O (3 × 20 mL), filtered and dried.  An aliquot of the dried filtrate (713 mg) was dissolved in 
5% CH3CN to a concentration of 25 mg/mL and purified by HPLC using a gradient of 5-100% 
CH3CN over 45 min, employing a Waters Sunfire Prep C-18 column (10 µm, 90 Å, 10 × 250 
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mm) until 70 mg of the sample was collected for biological activity screening. The isolated 
compound (4% yield) was a yellow viscous gel. IR vmax 3036, 1684, 1474, 1200, 1123 cm-1; 1H 
NMR and 13C NMR, see table S3 in Supporting information. HRESIMS m/z 393.9650 [M]+ 
(calcd for C13H1879Br2O3N, 393.9654). 
 
3,5-(dibromo-4-methoxyphenyl)acetic acid (2a) 
2a was prepared in 21% yield according to the method described by Weller et al. 24 Spectral data 
matched those previously reported. 
 
2-(3,5-dibromo-4-methoxyphenyl)-N-(5-(dimethylamino)pentyl)acetamide (2b)  
0.25 mL 5-(dimethylamino)amylamine (1.61 mmol, 1.05 equiv.) was added to a stirred solution 
of 2a (494.0 mg, 1.53 mmol) and HBTU (580 mg, 1.53 mmol, 1.0 equiv.) in 5 mL DMF and 
1.06 mL DIPEA (6.12 mmol, 4 equiv.). The reaction mixture was stirred overnight at rt before 
being diluted with 20 mL EtOAc, washed with 2 × 25 mL 10% citric acid, 25 mL 10% NaHCO3 
and 25 mL sat. brine. The EtOAc extract was dried over Na2SO4, filtered and concentrated in 
vacuo to yield a yellow oil. No further purification was performed. 1H NMR (400 MHz, CDCl3): 
δ = 7.36 (s, 2H), 3.79 (s, 3H), 3.34 (s, 2H), 3.14 (q, J = 6.0 Hz, 2H), 2.28 (m, 2H), 2.24 (s, 6H), 
1.47 (m, 2H), 1.40 (m, 2H), 1.24 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3): δ = 170.1 (C), 
153.0 (C), 134.2 (C), 133.5 (CH), 118.2 (C), 60.7 (CH3), 59.1 (CH2), 45.1 (CH3), 41.8 (CH2), 
39.7 (CH2), 29.1 (CH2), 26.8 (CH2), 24.3 (CH2) ppm. HRESIMS m/z 435.0279 [M + H]+ (calcd 





380 mg of 2b (0.87 mmol) was dissolved in 5 mL CH2Cl2 and 5 mL 1 M K2CO3 solution was 
added. The resulting mixture was stirred at room temperature for 15 min before 0.41 mL of 
methyl iodide (8.70 mmol, 10 equiv.) was added and the reaction stirred overnight. The pH of 
the reaction was adjusted to 7 with 2 M HCl. All volatiles were evaporated and the crude solid 
material (537 mg) was dissolved in CH2Cl2. Silica was added and the crude material was 
adsorbed onto the silica under vacuum. Silica column purification was performed using a 
mixture of HOAc:H2O:MeOH:EtOAc (3:2:3:3) and EtOAc 1:9 as eluent. A final purification of 
the isolated 237 mg of 2 with semi-preparative reversed-phase HPLC was necessary. The 
isolated 2 was dissolved in 5% CH3CN to a concentration of 25 mg/mL and HPLC purification 
was performed employing a Waters Sunfire Prep C-18 column (10 µm, 90 Å, 10 × 250 mm) 
using a gradient of 16-40% CH3CN in H2O over 40 min until 50 mg (13% yield) of 2 was 
collected. IR vmax 3019, 2400, 1600, 1422, 1218 cm-1; UV (MeOH) λmax 220 nm; 1H NMR and 
13C NMR, see table S3 in Supporting information. HRESIMS m/z 449.0439 [M]+ (calcd for 
C17H2779Br2O2N2, 449.0440).  
 
Acetylcholinesterase Inhibition Assay 
AChE activity was measured by Ellman’s method29, 30 using acetylthiocholine chloride (0.25, 0.5 
or 1 mM) as a substrate in 100 mM potassium phosphate buffer pH 7.4 at 25 oC, and electric eel 
AChE as a source of enzyme (final concentration in the test 0.0075 U/mL). Hydrolysis of 
acetylthiocholine chloride was followed on a Kinetic Microplate Reader (Dynex Technologies) 
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at 405 nm. Stock solutions (2 mg/mL) of 1 and 2 were prepared in deionised H2O and DMSO, 
respectively. AChE inhibition by 1 and 2, progressively diluted in H2O, was monitored for 5 
min. All readings were corrected for their appropriate blanks and a run with only 
acetylthiocholine chloride served as assay positive control. In the case of 2, the blank reactions 
without the inhibitor were run in the presence of the appropriate dilution of DMSO. Every 
measurement was repeated at least three times. 
 
Antibacterial Assay 
Test strains used were Staphylococcus aureus (ATTC 9144), Escherichia coli (ATCC 25922), 
Pseudomonas aeruginosa (ATTC 27853), and Corynebacterium glutamicum (ATTC 13032). All 
isolates were grown at 37 °C in Mueller Hinton Broth (MHB; Difco Laboratories). Bacterial 
growth was continuously monitored with an Envision plate reader (Perkin Elmer). The test was 
performed in 96-well Nun microtitre plates, in which 50 μL of test fractions dissolved in H2O 
were incubated with 50 μL of a suspension of an actively growing (log phase) culture of bacteria 
diluted to a starting concentration of approximately 5 × 105 cells per well. The antimicrobial 
peptide, cecropin B (25 μM), was used as a positive control. The minimum inhibitory 
concentration (MIC) was defined as the minimum concentration resulting in no change in optical 
density after incubation for 24 h at 37 °C. Compounds were tested at concentrations ranging 






Supporting Information. 1D and 2D NMR and HREIMS data of both natural and synthetic 1 
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